Lapatinib Terminated Phase 2 Trials for cancer treatment / Malignancies / Ovarian / Relapses Treatment

Indications	Status	Purpose	Phase
DBCOND0020788 (cancer treatment) DBCOND0034613 (Malignancies) DBCOND0036457 (Ovarian) DBCOND0047612 (Relapses)	Terminated	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02294786	Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer	Octreotide (DB00104) Lapatinib (DB01259) Capecitabine (DB01101)
NCT00888810	Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer	Topotecan (DB01030) Lapatinib (DB01259)
NCT00447226	Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists	Lapatinib (DB01259)